Physician profile
Zeba Vanek
NPI 1043233869
$2,030.14
in general payments reported to CMS, 2019-2025
20 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $133 · 2024: $240 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Travel and Lodging: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.03 |
| Travel and Lodging | $911.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,217.17 | 2025 | Vercise, General - Dbs |
| Ucb, INC. | $198.08 | 2023-2025 | Zilbrysq, Fintepla, Nayzilam |
| Grifols USA, LLC | $79.63 | 2024-2025 | Gamunex-C |
| Octapharma USA, INC. | $54.03 | 2023-2024 | Panzyga |
| Mdd US Operations, LLC | $52.85 | 2024 | Gocovri |
| Coloplast Corp | $50.84 | 2023-2025 | Speedicath |
| Argenx US, INC. | $49.47 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $44.55 | 2025 | Xeomin, Inbrija |
| Procept Biorobotics Corporation | $43.52 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Alexion Pharmaceuticals, INC. | $35.97 | 2023 | Ultomiris |
| Abbvie INC. | $33.36 | 2025 | |
| Amgen INC. | $24.37 | 2024 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $23.88 | 2025 | Austedo Xr |
| Livanova USA, INC. | $19.91 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ethicon US, LLC | $19.16 | 2025 | Evarrest, Stratafix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $17.71 | 2025 | Rytary |
| Kedrion Biopharma, INC. | $17.54 | 2025 | Gammaked, Koate, Albuked |
| Otsuka America Pharmaceutical, INC. | $17.36 | 2025 | Rexulti |
| Genentech USA, INC. | $16.55 | 2025 | Ocrevus Zunovo |
| Teleflex LLC | $14.19 | 2025 | Barrigel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeba Vanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.